<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651676</url>
  </required_header>
  <id_info>
    <org_study_id>PI2011_843_0006</org_study_id>
    <secondary_id>2011-A01653-38</secondary_id>
    <nct_id>NCT01651676</nct_id>
  </id_info>
  <brief_title>Estimation of the VQ11 Auto-questionnaire, to Follow Patients With Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>EPIC</acronym>
  <official_title>Evaluation of the VQ11 Auto-questionnaire of Quality of Life in Pneumology Investigation, During the Implementation of a Long-acting Bronchodilator Treatment of Patients With COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the capacity of the auto-questionnaire of quality of
      life, VQ11, to follow the evolution of patients with COPD (Chronic obstructive pulmonary
      disease) in stable state (without exacerbation in the previous 6 weeks) (3 months +/-15 days)
      during the implementation of a LABD (Long-acting bronchodilator) treatment.

      The main objective is to compare the total Score of the VQ11 auto-questionnaire before and
      after LABD. A decrease of 5 points of the total score mimicking an improvement in the quality
      of life linked to health, specifically in the COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of the VQ11 auto-questionnaire of quality of life in pneumology investigation,
      during the implementation of a long-acting bronchodilator treatment of patients with COPD.

      Two visits per patient are planned:

      V1: After complete information and collection of the written consent, the pulmonologists ask
      the patients participating in the study to fill out the VQ11 questionnaire, 2 visual
      analogical scales concerning the dyspnoea and the physical activity, the short IPAQ version
      and the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional
      exploration) is also realized during this medical exam.

      V2 (3 months after the treatment setup, at day90 ± 15): the pulmonologists ask the patients
      participating in the study to fill out the VQ11 questionnaire, 2 visual analogical scales and
      Likert scales concerning the dyspnoea and the physical activity, the short IPAQ version and
      the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional
      exploration) is also realized during this medical exam.

      Inclusion period : 6 months; Study participation period / patient : 3 months; Complete study
      duration : 9 months
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VQ11 score</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To compare changes of total Score of the VQ11 auto-questionnaire before and after LABD (decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VQ11 and visual analogical scale regarding daily activity</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To estimate the daily activity by a dedicated visual analogical scale. Variations between the two visits will be analysed in correlation to VQ11 changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFE</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>Respiratory functional exploration (RFE) performed at rest (plethysmography) before and three months after LABD treatment initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VQ11 sub-scores</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To estimate the impact of an LABD treatment on patients with COPD before and three months after treatment initiation through the three sub-dimensions of the VQ11 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Likert scales</measure>
    <time_frame>V2 (3 months after V1)</time_frame>
    <description>To estimate the evolution of dyspnoea and the daily activity by Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VQ11 and visual analogical scales regarding dyspnoea</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To estimate the dyspnoea by a dedicated visual analogical scale. Variations between the two visits will be analysed in correlation to VQ11 changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bi-directional visual analogical scale regarding dyspnoea</measure>
    <time_frame>V2 (3 months after V1)</time_frame>
    <description>To estimate the evolution of dyspnoea since the LABD initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bi-directional visual analogical scale regarding daily activity</measure>
    <time_frame>V2 (3 months after V1)</time_frame>
    <description>To estimate the evolution of daily activity since the LABD initiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To estimate the impact of an LABD treatment on patients with COPD before and three months after treatment initiation using the SGRQ change between the two visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea evolution assessed by mMRC</measure>
    <time_frame>V1 (at baseline), V2 (3 months after V1)</time_frame>
    <description>To estimate the impact of the LABD treatment on dyspnoea of patients with COPD before and three months after treatment initiation through the change of the Modified Medical Research Council dyspnoea scale (mMRC).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>COPD arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VQ11 validation:
Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VQ11 validation</intervention_name>
    <description>Two visits per patient are planned: V1 and V2.
For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)
LABD treatment consist in β 2 agonists or anticholinergic drug.</description>
    <arm_group_label>COPD arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD patient with stage II, III ou IV justifying a LABD

          -  Patient in stable state (without exacerbation in the previous 6 weeks)

          -  Clinical criteria: dyspnoea stage I ou more (MMRC scale)

          -  Adult over 18 years old.

          -  Patients naïve from LABD treatment.

        Exclusion Criteria:

          -  Other associated pathology (bronchiectasia...)

          -  Heart disorder with a prevailing role in the dyspnoea

          -  Cardiac decompensation in the previous year

          -  Pregnancy and lactating

          -  Women in genital activity without efficient contraception method (IUD or
             estrogen-progestin pill)

          -  Lack of social insurance

          -  Patient non compliant to protocol, at the investigator's appreciation

          -  Simultaneous participation to other clinical trial.

          -  adult under judicial protection (tutor or curator).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles DAYEN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles DAYEN, MD</last_name>
    <phone>03.22.66.80.60</phone>
    <email>dayen.charles@chu-amiens.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Loic FIN, PhD</last_name>
    <phone>+333 22 66 80 60</phone>
    <email>fin.loic@chu-amiens.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas BENOIT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas BENOIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier CARRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie BETHEMBOS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Chauny</name>
      <address>
        <city>Chauny</city>
        <zip>02300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Compiègne</name>
      <address>
        <city>Compiegne</city>
        <zip>60200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Médical</name>
      <address>
        <city>Compiegne</city>
        <zip>60200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain LEPILLIEZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain LEPILLIEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Creil</name>
      <address>
        <city>Creil</city>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard LAMARQUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gerard LAMARQUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médical</name>
      <address>
        <city>Denain</city>
        <zip>59220</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre GRIGNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre GRIGNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de DOUAI</name>
      <address>
        <city>Douai</city>
        <zip>59507</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Jacques MONOD</name>
      <address>
        <city>Le Havre</city>
        <zip>76083</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean QUIEFFIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Quieffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Médical</name>
      <address>
        <city>Le Havre</city>
        <zip>76600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PEREZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tierry PEREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François MUIR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François MUIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de St Quentin</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youcef DOUADI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Youcef DOUADI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle LECUYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zac Gouraud</name>
      <address>
        <city>Soissons</city>
        <zip>02200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Résidence Saint Michel</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VQ11 questionnaire</keyword>
  <keyword>COPD</keyword>
  <keyword>LBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

